Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Department of Surgery, Mayo Clinic, Rochester, MN, USA.
Lancet Gastroenterol Hepatol. 2019 Jul;4(7):559-570. doi: 10.1016/S2468-1253(19)30081-0.
Pancreatic neoplasms have high morbidity and dismal prognosis. Substantial progress in translational research and advances in scanner technology have resulted in rapid integration of molecular radionuclide imaging of pancreatic neoplasms into mainstream clinical practice. Metabolic imaging with F-FDG PET has extensive utility in the staging, assessment of treatment response, and follow-up of pancreatic ductal adenocarcinoma. Integrated PET/MRI has the potential to further expand this utility and lead to innovative applications. Somatostatin receptor PET imaging has had a profound effect on the evaluation and management of pancreatic neuroendocrine tumours. Peptide receptor radionuclide therapy is a new frontier in personalised medicine because it customises treatment to the unique biological features of a patient and the molecular signature of the patient's tumour. Further investigation is needed to optimise use of advanced molecular imaging techniques and novel radiotracers to achieve better outcomes for patients with pancreatic neoplasms.
胰腺肿瘤发病率高，预后差。转化研究取得了实质性进展，扫描仪技术也不断进步，使得胰腺肿瘤的分子放射性核素成像迅速融入主流临床实践。胰腺导管腺癌的分期、治疗反应评估和随访中广泛应用 F-FDG PET 的代谢成像。PET/MRI 整合有可能进一步扩大其应用范围并带来创新应用。生长抑素受体 PET 成像对胰腺神经内分泌肿瘤的评估和管理产生了深远影响。肽受体放射性核素治疗是个性化医学的新前沿，因为它根据患者的独特生物学特征和肿瘤的分子特征来定制治疗方案。需要进一步研究以优化先进的分子成像技术和新型放射性示踪剂的使用，从而为胰腺肿瘤患者带来更好的治疗效果。
